Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study This investigator-initiated, phase II, ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces the first patient enrollments in “A pilot study of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback